Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adcock Ingram Holdings Ltd.

www.adcock.co.za

Latest From Adcock Ingram Holdings Ltd.

Deals Shaping The Medical Industry, July/August 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced May and June 2014.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, June 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.

BioPharmaceutical Consumer

Deals In Depth: September 2013

Biogen and Isis teamed up for the fourth time in a new deal worth $450 million, focused on CNS disorders; Stryker gained robotic-assisted surgery expertise in its $1.4 billion acquisition of MAKO Surgical. Biopharma financing more than doubled in September compared with the previous month, reaching $1.7 billion and boosted by KV Pharma’s $375 million offering; device fundraising also increased, to $205 million, driven by early-stage venture rounds.

BioPharmaceutical Medical Device

Biopharma Dealmaking Quarterly Statistics, Q3 2013

Biopharma financing in Q3 2013 totaled $4.6 billion, a 58% drop from the second quarter; Perrigo’s $8.3 billion acquisition of Elan made up more than half of the M&A dollar value; and marketed products made up the majority of licensed products.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Adcock Ingram Ltd.
  • EJ Adcock Pharmacy
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Africa
      • South Africa
  • Parent & Subsidiaries
  • Adcock Ingram Holdings Ltd.
  • Senior Management
  • Kevin Wakeford, CEO
    Andrew G Hall, Fin. Dir.
    Werner van Rensburg, COO
  • Contact Info
  • Adcock Ingram Holdings Ltd.
    Phone: (27) 11 635 0000
    Private Bag x69
    Bryanston, 2021
    South Africa
Advertisement
Advertisement
UsernamePublicRestriction

Register